BiondVax Signs Exclusive Worldwide License Agreement To Develop And Commercialize A Novel Anti-IL-17 Antibody For Treatment Of Autoimmune And Inflammatory Diseases Including Psoriasis
Portfolio Pulse from Benzinga Newsdesk
BiondVax has signed an exclusive worldwide license agreement to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis.

June 05, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BiondVax's exclusive license agreement to develop and commercialize a novel anti-IL-17 antibody could potentially expand its product portfolio and address a significant market.
The exclusive worldwide license agreement allows BiondVax to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis. This could potentially expand the company's product portfolio and address a significant market, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100